Form 4: BioCryst Legal Officer Sells Shares Under 10b5-1 Plan

BioCryst Pharmaceuticals' Chief Legal Officer, Alane P. Barnes, executed pre-planned sales of common stock totaling 161,680 shares following the exercise of stock options.

Summary

• Alane P. Barnes, Chief Legal Officer of BioCryst Pharmaceuticals Inc. (BCRX), reported transactions involving the company's common stock.
• On December 1, 2025, Barnes acquired 91,004 shares of common stock by exercising employee stock options at a price of $3.22 per share.
• Concurrently on December 1, 2025, Barnes sold 91,004 shares of common stock at a weighted average price of $7.1042, with individual sales ranging from $7.015 to $7.190.
• On December 2, 2025, an additional 50,906 shares of common stock were sold at a weighted average price of $7.2136, with individual sales ranging from $7.180 to $7.255.
• On December 3, 2025, a further 19,770 shares of common stock were sold at a weighted average price of $7.65.
• All reported transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Barnes on August 13, 2025, indicating they were automatic and not discretionary.
• Following these transactions, Barnes' direct beneficial ownership of common stock decreased from 507,156 shares (after option exercise) to 345,476 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the execution under a pre-planned 10b5-1 plan mitigates concerns about opportunistic timing. The transactions represent a routine personal financial event for the executive.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which demonstrates transparency and reduces concerns about opportunistic insider selling.
• The exercise of stock options at $3.22 and subsequent sales at significantly higher prices (ranging from $7.1042 to $7.65) indicate a profitable event for the reporting person.

Negatives

• The net effect of the transactions is a reduction in the Chief Legal Officer's direct beneficial ownership of common stock by 161,680 shares, which some investors might interpret as a negative signal, despite the pre-planned nature.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a routine occurrence across all industries. They typically reflect an individual's personal financial planning rather than a direct commentary on the company's immediate prospects or industry trends.

Corporate Governance

Stakeholder Impact

• Shareholders: May note the reduction in an executive's direct shareholdings, though the pre-planned nature under Rule 10b5-1 typically lessens any negative interpretation.

Key Dates

Recommendation

The filing details routine insider transactions executed under a pre-planned Rule 10b5-1 trading plan. These transactions, while involving a significant number of shares for an individual, do not indicate a change in the company's fundamental outlook or strategic direction. Therefore, the filing alone does not warrant a change in investment recommendation, suggesting a 'hold' position for existing investors.

Keywords

BioCryst Pharmaceuticals, BCRX, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Alane P. Barnes, Chief Legal Officer, 10b5-1 Plan